Member Info for Let-It-Roll

They know it's only going one way - up!

:-)

If it's a hedge against a long.... then we can see we have a first fund onboard publically.

Or is it a hedge against a long investment?

Hope they burn in hell. A fund taking a position AGAINST life saving treatment.

Open Short Positions in Hemogenyx

Fund % Short Change Date Changed

Hamilton Stuart Capital Ltd 0.56% 0.00% 15 Sep 2025

Total 0.56%

Hemogenyx Pharmaceuticals PLC on Wednesday said the third patient has been successfully treated in an ongoing phase 1 clinical trial for a form of leukaemia.

The London-headquartered biopharmaceutical company focused on treatments for blood diseases said the treatment was for adults with relapsed/refractory acute myeloid leukaemia [AML], a type of blood cancer.

The trial is of HG-CT-1, the company's proprietary chimeric antigen receptor t-cell therapy.

Notably, original acute myeloid leukaemia cells were not detectable in the patient via standard testing methods, following treatment.

"The treatment was well tolerated and met the trial's predefined initial safety criteria. Importantly, early indications of clinical efficacy have been observed. Preliminary assessment shows that original AML cells were not detectable in the patient using standard testing methods. The patient will continue to be monitored in line with the [US] Food & Drug Administration-approved trial protocol to evaluate the achievement of the study's secondary endpoints described below," Hemogenyx said.

Hemogenyx Chief Executive Officer & Co-Founder Vladislav Sandler said: "The successful treatment of the third patient marks another important milestone for Hemogenyx Pharmaceuticals and for patients battling relapsed or refractory AML. We are encouraged by the favorable safety profile observed to date, together with the early signals of efficacy. These results reinforce the promise of HG-CT-1 as a potential new therapy for one of the most aggressive and intractable forms of leukemia. We remain committed to advancing the clinical development of this therapy to address a critical unmet medical need, while also creating long-term value for our shareholders."

Hemogenyx shares jumped 21% to 1,494.69 pence each on late Wednesday morning in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

It's a little 300 share sell order set at £25. It's been there for the last couple of days.

Yep. They are big order filling for sure.

The MM's are shaking that tree again. Question is: Do we have another RNS logged for tomorrow? Capitol Hill and all that.

Games afoot. Again.

I was saying it tongue in cheek! that order means nothing.

:-)

Chunky buy: 14:42:38 1,600.00 1,989 31.82k A

17001500

-

1565111

Depth 21

14:23 700 1500

14:21 773 1455

14:21 MREX 1,000 1450

14:26 SING 1,000 1425

13:09 500 1415

10:08 PEEL 1,000 1410

14:18 WINS 1,000 1400

14:23 STFL 1,000 1400

11:46 SCAP 1,000 1365

09:18 300 1350

11:09 1 1345

11:02 30 1340

07:58 50 1160

07:58 100 1140

07:50 25 1060

07:50 9 900

07:50 50 888

07:50 50 750

07:50 50 728

07:50 15 650

07:50 2 500

17 Depth

1565 11 13:15

1580 1,000 SCAP 11:46

1585 100 13:15

1600 1,989 08:57

1600 60 09:00

1600 1,000 WINS 14:18

1615 1,000 STFL 14:23

1625 1,000 PEEL 10:08

1630 1,000 SING 14:26

1635 100 14:23

1650 243 14:18

1650 1,000 MREX 14:21

1800 1,000 08:07

1800 25 08:12

1800 84 08:21

1850 1,000 08:33

2500 300 08:18

Also, bear in mind there is lots of trickery behind the scenes by the MM's. Like dropping to just below 12 yesterday. If that had not happened, the 15% rise currently showing would have us at £16. and we'd have peaked pretty much at £20.

So I'm very happy tbh. The sp will continue rise, and those that have sold have gone now. So onwards and upwards. With more big players coming in rather than the 'instant profit' hungry traders.

Losta: I would suggest it is the same.

Think Vlad probably wants to have his big moment tomorrow on that.

Plenty of PI were here for the RNS, and have sold out. More fool them. They just aren't interested in the science.

BUT if you actually read the RNS, to remove AML completely within 28 days of treatment in a patient who was on their last dying legs is nothing short of a miracle.

Big pharma will know that.

Role on tomorrow and Capitol Hill.

Did J&J invite him?

:-)